We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.8%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.57B
AUM Growth
+$1.06B
Cap. Flow
+$745M
Cap. Flow %
7.79%
Top 10 Hldgs %
36.3%
Holding
159
New
27
Increased
34
Reduced
20
Closed
32

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$202M
2
COO icon
Cooper Companies
COO
+$180M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$78.3M
4
SHPG
Shire pic
SHPG
+$77.9M
5
WMGI
Wright Medical Group Inc
WMGI
+$75.3M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$240M
2
VTRS icon
Viatris
VTRS
+$184M
3
AGN
Allergan Inc
AGN
+$107M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$89.3M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$43.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.95%
2 Financials 0.07%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
76
Jazz Pharmaceuticals
JAZZ
$16.2B
$18.5M 0.19%
115,000
– –
BHC icon
77
Bausch Health
BHC
$1.68B
$18.1M 0.19%
138,000
– –
GWPH
78
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$17.9M 0.19%
+221,000
New +$19.6M
UNH icon
79
UnitedHealth
UNH
$387B
$17.3M 0.18%
+200,000
New +$16.9M
SAGE
80
DELISTED
Sage Therapeutics
SAGE
$16.9M 0.18%
+537,335
New +$15.6M
PRQR icon
81
ProQR Therapeutics
PRQR
$246M
$16.3M 0.17%
+950,000
New +$15.2M
COV
82
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$15.6M 0.16%
180,600
– –
BMY icon
83
CALL
Bristol-Myers Squibb
BMY
$130B
$15.4M 0.16%
+300,000
New +$15M
PBYI icon
84
CALL
Puma Biotechnology
PBYI
$404M
$14.3M 0.15%
60,000
-25,000
-29% -$5.13M
ELV icon
85
Elevance Health
ELV
$83.3B
$14.2M 0.15%
118,500
+58,500
+98% +$6.71M
SVA
86
DELISTED
Sinovac Biotech, Ltd
SVA
$13.6M 0.14%
2,821,500
+1,184,000
+72% +$6.36M
LITS
87
Lite Strategy Inc
LITS
$33.2M
$13.3M 0.14%
96,225
– –
ISEE
88
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$13.2M 0.14%
+338,800
New +$13.3M
SLXP
89
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$12.8M 0.13%
+82,000
New +$11.9M
FPRX
90
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$12.6M 0.13%
1,075,400
– –
AGEN
91
Agenus
AGEN
$278M
$11.2M 0.12%
182,712
– –
HZNP
92
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$11M 0.11%
896,000
+350,000
+64% +$4.07M
XOMA
93
DELISTED
Xoma
XOMA
$10.3M 0.11%
121,850
– –
MRGE
94
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
$10.2M 0.11%
4,628,500
– –
VIRX
95
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$8.57M 0.09%
5,714
– –
PTX
96
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$8.24M 0.09%
107,300
-5,760
-5% -$454K
ALIM
97
DELISTED
Alimera Sciences
ALIM
$8.13M 0.08%
100,000
– –
RDHL
98
Redhill Biopharma
RDHL
$4.26M
$7.98M 0.08%
606
– –
XNCR icon
99
Xencor
XNCR
$1.47B
$7.81M 0.08%
838,700
+37,000
+5% +$374K
VTRS icon
100
Viatris
VTRS
$20.9B
$7.69M 0.08%
169,100
-3,783,600
-96% -$184M
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2014 Portfolio in Review

As of Q3 2014, OrbiMed held 159 positions worth $9.57B, up 12% from $8.52B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed deployed $745M of net new capital in Q3 2014, opening 27 new positions and adding to 34 existing holdings. Its largest new stake was Cooper Companies: 4,570,800 shares worth $178M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Viatris, an estimated $184M trimmed.

  • OrbiMed's largest Q3 2014 buy was Cooper Companies: 4,570,800 shares worth $178M.
  • OrbiMed added most to Allergan plc in Q3 2014, an estimated $202M increase.
  • OrbiMed's biggest Q3 2014 reduction was Viatris, cutting an estimated $184M.
  • OrbiMed fully exited INTERMUNE INC in Q3 2014, selling an estimated $240M.
  • OrbiMed's ten largest holdings make up 36% of its $9.57B portfolio in Q3 2014.
  • OrbiMed opened 27 new positions and closed 32 in Q3 2014.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $9.57B.

Based on OrbiMed's 13F filing for Q3 2014, filed 14 Nov 2014.